Castle Biosciences, Inc. $CSTL Shares Sold by Allianz Asset Management GmbH

Allianz Asset Management GmbH decreased its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 9.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 648,351 shares of the company’s stock after selling 65,391 shares during the period. Allianz Asset Management GmbH owned about 2.23% of Castle Biosciences worth $14,763,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC increased its position in shares of Castle Biosciences by 139,100.0% during the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock worth $32,000 after acquiring an additional 1,391 shares during the last quarter. State of Alaska Department of Revenue purchased a new position in Castle Biosciences in the third quarter valued at about $35,000. CWM LLC grew its stake in Castle Biosciences by 80.6% during the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock valued at $44,000 after purchasing an additional 853 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after purchasing an additional 2,648 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Castle Biosciences by 256.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,791 shares of the company’s stock worth $57,000 after purchasing an additional 2,009 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CSTL has been the subject of several research analyst reports. Guggenheim increased their target price on Castle Biosciences from $43.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, February 2nd. KeyCorp reiterated an “overweight” rating and set a $50.00 price objective on shares of Castle Biosciences in a research note on Thursday, January 29th. Canaccord Genuity Group boosted their target price on shares of Castle Biosciences from $37.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Castle Biosciences in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Castle Biosciences currently has an average rating of “Moderate Buy” and an average price target of $47.14.

Castle Biosciences Stock Performance

Castle Biosciences stock opened at $32.75 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.31. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $44.28. The company has a fifty day moving average price of $39.36 and a two-hundred day moving average price of $29.72. The company has a market cap of $955.97 million, a PE ratio of -72.78 and a beta of 1.06.

Insider Buying and Selling

In other Castle Biosciences news, insider Derek J. Maetzold sold 817 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $37.99, for a total value of $31,037.83. Following the transaction, the insider owned 83,698 shares of the company’s stock, valued at $3,179,687.02. This trade represents a 0.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Tobin W. Juvenal sold 4,693 shares of Castle Biosciences stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $35.58, for a total value of $166,976.94. Following the completion of the transaction, the insider owned 84,595 shares of the company’s stock, valued at approximately $3,009,890.10. The trade was a 5.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 39,425 shares of company stock worth $1,539,720 over the last quarter. 6.50% of the stock is owned by company insiders.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.